You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長春高新(000661.SZ):子公司注射用伏欣奇拜單抗在境內獲批上市

格隆匯7月2日丨長春高新(000661.SZ)公佈,近日,長春高新技術產業(集團)股份有限公司從國家藥品監督管理局網站獲悉,控股子公司長春金賽藥業有限責任公司(簡稱“金賽藥業”)申報的注射用伏欣奇拜單抗已經國家藥品監督管理局批準上市。

注射用伏欣奇拜單抗是公司研發的一款新型全人源抗IL-1β單克隆抗體藥物,屬於治療用生物製品1類新藥,可特異性結合人IL-1β,阻斷IL-1β誘導的炎性介質產生,用於成人痛風性關節炎急性發作患者。

注射用伏欣奇拜單抗已完成的關鍵臨牀試驗“評估注射用金納單抗治療痛風性關節炎的有效性和安全性的隨機、雙盲雙模擬、陽性對照、多中心的Ⅲ期臨牀試驗”結果顯示,伏欣奇拜單抗6小時即可快速起效,72小時鎮痛效果與激素相當,6個月內首次復發風險降低近90%,且安全性良好。公司注射用伏欣奇拜單抗作爲國內首個獲批用於治療痛風性關節炎急性發作的IL-1抑制劑,其精準、長效抗炎的優勢將爲痛風患者帶來新的治療選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account